**5. Action plan and future prospective**

As indicated by the literature from the pharmaceutical engineering, medical, and academic domains, an action plan to sustain future breakthroughs and clinical success is necessary to channel the increased interest in this topic. To continue these discussions and see the successful application of more drug delivery systems in ophthalmology, we propose: (i) increased collaboration at academic institutions between basic and applied scientific teams, where many novel drug delivery systems are discovered; (ii) collaboration between pharmaceutical corporations and researchers in basic and applied sciences to speed up technology transfer and enable the creation and sale of innovative prions; (iii) standardised procedures for collecting ocular tissue samples for pharmacokinetic comparisons. Samples of posterior ocular tissues like the choroid, retinal pigment epithelium, neuroretina (macula and peripheral retina), and sclera should be obtained consistently to improve data comparison; (iv) To help sponsors choose the best route to regulatory approval of innovative ocular drug delivery systems, there should be clear guidelines, including early and regular communication with regulatory bodies; (v) gatherings and organisations that foster conversation between fundamental, applied, and clinical researchers in order to support upcoming joint efforts in the creation of medical devices and drugs as well as in ophthalmology translational research; (vi) Rewards for participating persons and organisations; (vii) Journals that support and welcome translational research papers in subjects including the outcomes of preclinical testing, the creation of analytical techniques, plans for the advancement of investigational medications, and critical evaluation of trials that fall short of their objectives.
